• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Study: Prevalence of myopic macular degeneration in those 85 years and older

News
Article

(Image Credit: AdobeStock/kohanova1991)

(Image Credit: AdobeStock/kohanova1991)

The takeaway message from a population-based study of very old, highly myopic individuals found a high risk of developing myopic maculopathy and marked visual impairment,1 according to first author Mukharram M. Bikbov, MD, from the Ufa Eye Research Institute, Ufa, Russia.

The investigators explained that with older age a risk factor for the development of myopic macular degeneration (MMD), the aging of a young myopic generation may result in even more visual impairment and blindness as the result of myopic macular degeneration.2

They conducted a study to assess the prevalence of and associations of MMD in very old individuals recruited in a population-based manner. They then compared the results with the findings from another population-based study previously conducted with a similar study design and in the same geographic region on younger individuals.

The Ural Very Old Study included 1,526 of 1,882 eligible individuals who were 85 years and older; 60.9% of these (930 individuals; mean age, 88.6 years) had fundus images available for assessment.

The authors explained that MMD was defined by the presence of macular patchy atrophies (stages 3 and 4 as defined by the Pathologic Myopia Study Group3).

MMD prevalence

MMD was found in 21 of 930, for a prevalence rate of 2.3% (95% confidence interval [CI], 1.3–3.3). Ten individuals had stage 3 MMD and 11 participants had stage 4 MMD.

In those 2 stages, the authors reported that “the prevalence of binocular moderate-to-severe vision impairment was 4 of 10 (40%; 95% CI, 31–77) and 7 of 11 (64%; 95% CI, 30–98), respectively, and the prevalence of binocular blindness was 2 of 10 (20%; 95% CI, 0–50) and 3 of 11 (27%; 95% CI, 0–59), respectively.”

An analysis of the axial lengths showed that in low myopia (axial length, 24.0 to <24.5 mm), moderate myopia (axial length, 24.5 to <26.5 mm), and high myopia (axial length, ≥26.5 mm), the respective MMD prevalence rates in the right eyes were 0 of 46 eyes (0%), 3 of 40 eyes (8%; 95% CI, 0–16), and 7 of 9 (78%; 95% CI, 44–100) and the respective MMD prevalence rates in the left eyes were 1 in 48 eyes (2%; 95% CI, 0–6), 4 of 36 eyes (11%; 95% CI, 0–22), and 3 of 4 eyes (75%; 95% CI, 0–100).

Multivariable analysis showed that a higher MMD prevalence rate (odds ratio, 8.89; 95% CI, 3.43–23.0) and a higher MMD stage (beta, 0.45; B, 19; 95% CI, 0.16–0.22) (p < 0.001 for both comparisons) were correlated with longer axial length but not any other ocular or systemic parameter.

Bikbov and colleagues concluded, “The MMD prevalence (stages 3 and 4) in very old individuals increased 8.89-fold for each millimeter increase in the axial length, with a prevalence of 75% or higher in highly myopic eyes. In old age, highly myopic individuals have a high risk of eventually developing MMD with marked vision impairment.”

References:
  1. Bikbov MM, Gilmanshin TR, Kazakbaeva GM, Panda-Jonas S, Jonas JB. Prevalence of myopic maculopathy among the very old: The Ural Very Old Study. Invest Ophthalmol Vis Sci. 2024;65:29. doi: https://doi.org/10.1167/iovs.65.3.29
  2. Morgan IG, Ohno-Matsui K, Saw SM. Myopia. Lancet. 2012;379:1739–1748.
  3. Ohno-Matsui K, Kawasaki R, Jonas JB, et al. International classification and grading system for myopic maculopathy. Am J Ophthalmol. 2015;159:877–883.
Related Videos
Video 1 - "Challenging the Definition of Dry Eye- Interpreting Diagnostic Tests"
ASCRS 2024: ViaLase Updates on Nonincisional Glaucoma Treatment Targeting Trabecular Meshwork
Dr. Neda Nikpoor Shares Practical Techniques to Combat Unconscious Gender Bias and Promote Gender Equality in Ophthalmology
ASCRS 2024: George O. Waring, MD, shares early clinical performance of bilateral Odyssey implantation
ASCRS 2024: Deborah Gess Ristvedt, DO, discusses third-generation trabecular micro-bypass
Arjan Hura, MD, highlights the clinical and surgical updates at CIME 2024
© 2024 MJH Life Sciences

All rights reserved.